Supernus Pharmaceuticals (NASDAQ: SUPN) — Perfil da empresa, notícias e dados financeiros
Supernus Pharmaceuticals develops products for central nervous system diseases, focusing on epilepsy, Parkinson's, and migraines.
Supernus Pharmaceuticals
Supernus Pharmaceuticals (NASDAQ:SUPN) focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Their portfolio addresses conditions such as epilepsy, Parkinson's disease, and migraines, aiming to improve patients' lives through innovative therapies. Supernus is deeply invested in advancing its current projects in clinical development to expand its presence in the CNS market. By concentrating on unmet medical needs, the company strives to advance its lineup of products while also exploring potential new therapeutic areas. Through a blend of internal development and strategic acquisitions, Supernus aims to grow its product offerings and enhance its impact within the healthcare sector.
Resumo
Operações
Produtos e/ou serviços de Supernus Pharmaceuticals
- Trokendi XR, an extended-release version of topiramate, is used primarily for treating epilepsy and preventing migraines.
- Oxtellar XR is an extended-release oxcarbazepine medication designed to manage epilepsy and seizure disorders effectively.
- Qelbree is a non-stimulant treatment approved for managing attention deficit hyperactivity disorder (ADHD) in pediatric patients and adults.
- Aprocitentan, under development for resistant hypertension treatment, aims to address the needs of patients unresponsive to conventional therapies.
- SPN-812 is a novel, non-stimulant medication undergoing evaluation for potential use in treating attention deficit hyperactivity disorder (ADHD).
- SPN-810 is being developed to address impulsivity and aggression in patients with attention deficit hyperactivity disorder (ADHD), targeting a significant unmet need.
equipe executiva do Supernus Pharmaceuticals
- Jack A. KhattarFounder, President, CEO, Secretary & Director
- Timothy C. DecSenior VP & CFO
- Padmanabh P. BhattChief Scientific Officer & Senior VP of Intellectual Property
- Frank MottolaSenior VP & Chief Technology Operations Officer
- Jonathan RubinSenior VP of Research & Development and Chief Medical Officer
- Kevin T. AndersonCompliance Officer
- Taylor RaifordSenior Vice President of Sales
- William Todd HorichSenior VP & Chief Commercial Officer
- Bryan A. RoeckleinSenior VP & Chief Business Officer
- Jeff BozickSenior Vice President of Supply Chain
Últimas notícias sobre a Supernus Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Supernus Pharmaceuticals, em USD.
- Cap. de mercado
- 2,4 bi
- Receita (TTM)
- 830,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.9
- Dividend yield
- —
- Margem de lucro
- -13.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 719 mi | -36,9 mi | -38,6 mi | |
| 661,8 mi | 81,7 mi | 73,9 mi | |
| 607,5 mi | -5,3 mi | 1,3 mi | |
| 667,2 mi | 46,1 mi | 60,7 mi |